Kymera Therapeutics reported a third-quarter loss of $1.32 per share, missing the consensus estimate of a $1.26 loss by 4.8%. Revenue came in at zero against expectations of $6.05 million, a 100% miss and a 100% year-over-year decline. Earnings fell 46.7% from a year ago as the net loss widened to $132.0 million from $82.2 million. For a clinical-stage company, though, the income statement was not the story. Kymera paired the miss with Phase 1 KT-579 data that cleared its own stated bar and confirmed that the KT-621 BROADEN2 atopic dermatitis readout remains on its accelerated year-end 2026 timeline. Rising burn set against de-risking clinical progress is the central tension.

The quality of the miss is easy to explain. The company recognized no collaboration revenue after $65 million in the second quarter and $34.4 million in the first, once the Gilead milestones were fully booked. Management expects no further collaboration revenue in 2026, so the consensus revenue figure was optimistic. The more lasting issue is spending. R&D rose to $128.5 million from $74.1 million a year earlier, and it has climbed every quarter: $83.8 million in Q4 2025, $98.2 million in Q1, $119.5 million in Q2. The CFO guided to gradual but consistent operating-expense increases that accelerate once Phase 3 trials begin. Weighted shares rose to roughly 100 million from 87 million, which adds per-share pressure. The offset is a strong balance sheet. Cash and investments stood at $1.65 billion, and interest income of $15.3 million cushioned the operating loss. Runway is unchanged into 2029.

Scientifically, the quarter was a clear step forward. KT-579, Kymera's IRF5 degrader, showed median IRF5 degradation of at least 90% across multiple MAD dose levels, saturating by dose level 3 at about 94% in blood. Degradation in skin was comparable, a notable result since management had said a year ago that skin would likely be unmeasurable. Ex vivo IFN-beta inhibition reached 98%, compared with the 50-80% biomarker reduction management had set as its target through the first half. TNF-alpha, IL-12/23p40 and IL-1-beta were also suppressed by 87-94%. Safety was comparable to placebo, with no serious adverse events and no discontinuations. Management called the data better than expected, and the tone on the call was noticeably more confident. The program now has a defined next step: the roughly 30-patient, 16-week LUMORA lupus study, set to start by early 2027, with Sjögren's, IBD and RA expansion plans to come next year.

The near-term catalyst, however, is KT-621. BROADEN2's 16-week placebo-controlled portion is complete, and 98% of eligible patients rolled into the 52-week open-label extension. Topline data are due by year-end, pulled forward from the original mid-2027 guidance. A first Phase 3 AD trial is targeted for mid-2027, subject to regulatory discussions. Management has framed expectations around a "Dupixent ballpark" efficacy profile, with caveats on cross-trial comparisons. That makes the readout a genuinely binary event against a fairly high bar.

Bears have legitimate ammunition beyond the miss:

• The next development-candidate disclosure slipped from the second half of 2026 into 2027.
• Asthma enrollment in BREADTH is running slower because of strict criteria and higher screen-fail rates, although late-2027 timing is maintained.
• The runway language now refers to funding the KT-621 AD Phase 3 studies rather than a broader commitment, even as burn rises.
• Management is withholding KT-579 dose-response detail for competitive reasons.

The market setup reflects growing confidence heading into the readout. Investor sentiment remained negative but improved meaningfully, moving from -0.32 to -0.11. In the session before the report, shares were at $122.51, up 16.8% from the opening price after the August report and about 28% above the 200-day moving average of $95.81. The stock had rallied about 20% from its October 6 low of $101.75 and entered earnings roughly 4% below its late-August inter-earnings high of $127.85. Momentum and AVWAP trend readings are positive, while price trend is neutral. In short, the stock came into the report with a substantial run behind it, which raises the stakes for BROADEN2.

The bottom line is that the headline miss and zero revenue tell investors little about Kymera's trajectory. KT-579 materially de-risked a second first-in-class immunology asset, and KT-621 stays on schedule. Against that, spending is accelerating, collaboration funding has dried up and pipeline expansion was deferred. With $1.65 billion in cash, the company can afford its ambitions. The investment case now rests heavily on whether BROADEN2 delivers near-Dupixent efficacy by year-end.